Fundación Pública Gallega de Medicina Genómica (FPMGX) is a Spanish public reference institution that integrates genomic medicine into the public healthcare system, ensuring equitable access to clinically relevant genomic testing. It supports public health through advanced genomic technologies and translational research, with a focus on oncology and rare diseases.
FPGMX employs next-generation sequencing, transcriptomics, and bioinformatics for clinical diagnostics and biomedical research. Its close integration with the Galician public healthcare system (SERGAS) and the Health Research Institute of Santiago de Compostela (IDIS) enables rapid translation of research into clinical practice.
FPGMX’s participation in TETRIS is led by Dr Ana Vega, Principal Investigator and Work Package Leader. She is a Clinical Geneticist specialized in Molecular Genetics and Head of the Genetics in Cancer and Rare Diseases Group at the Health Research Institute of Santiago de Compostela. Her expertise includes molecular genetics, oncogenomics, and translational medicine, with a focus on interindividual variability in response to oncological treatments, particularly radiotherapy.
The FPGMX TETRIS team comprises Miguel E. Aguado-Barrera, expert in genomic and transcriptomic data analysis; Ana María Varela-Pazos, María de la Luz Couselo-Paniagua, and Nuria Salvador-Garrido from the Department of Radiation Oncology at CHUS, providing clinical expertise and biomarker integration; and Ramón Lobato-Busto from the Department of Medical Physics, contributing to the integration of biological data, dosimetry, and risk modelling.
Within TETRIS, FPGMX leads Work Package 5 (WP5) – Transcriptomics, focused on identifying blood-based gene expression biomarkers from retrospective and prospective cohorts. These transcriptomic signatures feed into risk prediction models (WP2) and are integrated into the CE-marked software tool (WP6) and digital twin prototypes (WP7).
In addition, FPGMX contributes to WP1, WP2, WP4, WP6, WP7, WP8, WP9, and WP10, supporting TETRIS’s goal of advancing personalised and safer radiotherapy through integrated, data-driven models.
